Pliant Therapeutics Receives FDA Fast Track Designation for PLN-101095 in Combination with Pembrolizumab for the Treatment of ICI-Refractory Solid Tumors

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/5/2026

1. ZS
2. LULU
3. IOT
4. SPY
5. PATH
6. DOCU
7. ASAN
8. NVDA
9. GWRE
10. CIEN

Go back to Pliant Therapeutics Receives FDA Fast Track Designation for PLN-101095 in Combination with Pembrolizumab for the Treatment of ICI-Refractory Solid Tumors
(NASDAQ: PLRX) Delayed: 1.16 +0.03 (2.65%)
Previous Close $1.13    52 Week High $ 
Open $1.12    52 Week Low $ 
Day High $1.19    P/E N/A 
Day Low $1.11    EPS $ 
Volume 559,896